Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-PD-L1 Antibody MEDI4736 in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC). A Multicenter Single-arm Phase II Trial.

NCT02572843 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT02572843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02572843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-PD-L1 Antibody MEDI4736 in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC). A Multicenter Single-arm Phase II Trial.
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
June 16, 2016
Completion date
March 19, 2024
Enrollment
68 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc non-small cell lung cancer